Spero Therapeutics Inc (SPRO) concluded trading on Wednesday at a closing price of $2.35, with 182.33 million shares of worth about $428.47 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 97.48% during that period and on Wednesday the price saw a gain of about 244.57%. Currently the company’s common shares owned by public are about 55.90M shares, out of which, 37.37M shares are available for trading.
Stock saw a price change of 245.49% in past 5 days and over the past one month there was a price change of 230.99%. Year-to-date (YTD), SPRO shares are showing a performance of 128.16% which increased to 58.78% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.51 but also hit the highest price of $1.53 during that period. The average intraday trading volume for Spero Therapeutics Inc shares is 129.39K. The stock is currently trading 220.34% above its 20-day simple moving average (SMA20), while that difference is up 224.31% for SMA50 and it goes to 132.23% higher than SMA200. Spero Therapeutics Inc (NASDAQ: SPRO) currently have 55.90M outstanding shares and institutions hold larger chunk of about 27.53% of that.
The stock has a current market capitalization of $131.39M and its 3Y-monthly beta is at 0.25. It has posted earnings per share of -$1.28 in the same period. It has Quick Ratio of 2.56 while making debt-to-equity ratio of 0.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SPRO, volatility over the week remained 61.97% while standing at 27.97% over the month.
Analysts are in expectations that Spero Therapeutics Inc (SPRO) stock would likely to be making an EPS of -0.32 in the current quarter, while forecast for next quarter EPS is -0.25 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.32 which is -0.32 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.33 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 111.42% while it is estimated to decrease by -893.10% in next year. EPS is likely to shrink at an annualized rate of 7.97% for next 5-years, compared to annual growth of 17.67% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Evercore ISI on December 20, 2024 offering an In-line rating for the stock and assigned a target price of $5 to it. Coverage by Evercore ISI stated Spero Therapeutics Inc (SPRO) stock as an Outperform in their note to investors on September 23, 2022, suggesting a price target of $8 for the stock. On October 01, 2021, Oppenheimer Downgrade their recommendations, while on January 22, 2021, H.C. Wainwright Reiterated their ratings for the stock with a price target of $40. Stock get a Buy rating from Berenberg on December 16, 2020.
